Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes. Biomed Pharmacother. 2024;175:116707.
Cation-independent mannose 6-phosphate receptor: From roles and functions to targeted therapies. J Control Release 2024;365:759-772.
Engineered therapeutic antibodies with mannose 6-phosphate analogues as a tool to degrade extracellular proteins. Front. Immunol. 2024.
Mannose 6-phosphate receptor-targeting antibodies preserve Fc receptor-mediated recycling. J Control Release 2023;358:465-475.
The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics. Biomater Sci 2020;8:3678-3684.
Mannose 6-phosphonate labelling: A key for processing the therapeutic enzyme in Pompe disease. J Cell Mol Med 2019;23:6499-6503.
Topological requirements for CI-M6PR-mediated cell uptake. Bioconjugate Chem. 2019; 30:2533-2538.
Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase. J Control Release 2018,269:15-23.
Design of potent mannose 6-phosphate analogues for the functionalization of lysosomal enzymes to improve the treatment of Pompe disease. Angew Chem Int Ed Engl 2016,55:14774-14777.
Why anticancer nanomedicine needs sugars? Curr Med Chem 2015 ;22(26):3014-24.
Identification of MRC2 and CD209 receptors as targets for photodynamic therapy of retinoblastoma using mesoporous silica nanoparticles. RSC Adv 2015, 5, 75167-72.
Mannose-6-phosphate receptor: a target for theranostics of prostate cancer. Angew Chem Int Ed Engl. 2015 ;54(20):5952-6.
Targeting multiplicity: the key for anti-cancer nanoparticles. Curr Med Chem. 2013, 20(15):1946-55.
